Patents by Inventor Maria Rita Fontana

Maria Rita Fontana has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10988511
    Abstract: Homologs of the E. coli proteins orf353, bacterial lg-like domain (group 1) protein (orf405), flu antigen 43 (orf1 364), NodT-family outer-membrane-factor-lipoprotein efflux transporter (orf1 767), gspK (orf3515), gspJ (orf3516), toriB-dependent siderophore receptor (orO597), fibrial protein (orf3613), upec-948, upec-1232. A chain precursor of the type-1 fimbria! protein (upec-1875), yapH homolog (upec-2820), hemolysin A (recp-3768), and Sel 1 repeat-containing protein (upec-521 1) from several pathogenic strains of E. coli have been identified with regions within the proteins that are conserved across all E. coli. Fragments corresponding to the conserved regions, especially immunogenic fragments such a linear B-epitopes, are provided.
    Type: Grant
    Filed: July 7, 2010
    Date of Patent: April 27, 2021
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Laura Serino, Maria Rita Fontana, Danilo Gomes Moriel
  • Publication number: 20180298064
    Abstract: Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunising against MNEC infections.
    Type: Application
    Filed: June 26, 2018
    Publication date: October 18, 2018
    Applicants: GlaxoSmithKline Biologicals SA, J. Craig Venter Institute, Inc.
    Inventors: Vega MASIGNANI, Danilo Gomes MORIEL, Francesco BERLANDA SCORZA, Nathalie NORAIS, Maria Rita FONTANA, Mariagrazia PIZZA, Laura SERINO, Hervé TETTELIN
  • Patent number: 10058600
    Abstract: Detoxified variants of the pathogenic E. coli ‘AcfD precursor’ (orf3526) have been identified that raise a substantially similar immune response in a subject as the native AcfD (orB526) protein. The detoxified variants may be further modified to have increased solubility as compared to the native AcfD (orf3526) protein.
    Type: Grant
    Filed: October 27, 2014
    Date of Patent: August 28, 2018
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Laura Serino, Maria Rita Fontana, Danilo Gomes Moriel
  • Patent number: 10035826
    Abstract: Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunizing against MNEC infections.
    Type: Grant
    Filed: May 9, 2016
    Date of Patent: July 31, 2018
    Assignees: GlaxoSmithKline Biologicals SA, J. Craig Venture Institute, Inc.
    Inventors: Vega Masignani, Danilo Gomes Moriel, Francesco Berlanda Scorza, Nathalie Norais, Maria Rita Fontana, Mariagrazia Pizza, Laura Serino, Herve Tettelin
  • Publication number: 20160244489
    Abstract: Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunising against MNEC infections.
    Type: Application
    Filed: May 9, 2016
    Publication date: August 25, 2016
    Applicants: GlaxoSmithKline Biologicals SA, J. Craig Venter Institute, Inc.
    Inventors: Vega MASIGNANI, Danilo Gomes MORIEL, Francesco BERLANDA SCORZA, Nathalie NORAIS, Maria Rita FONTANA, Mariagrazia PIZZA, Laura SERINO, Herve TETTELIN
  • Patent number: 9334313
    Abstract: Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunizing against MNEC infections.
    Type: Grant
    Filed: June 2, 2014
    Date of Patent: May 10, 2016
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Vega Masignani, Danilo Gomes Moriel, Francesco Berlanda Scorza, Nathalie Norais, Maria Rita Fontana, Mariagrazia Pizza, Laura Serino, Herve Tettelin
  • Patent number: 9101560
    Abstract: Variants of the pathogenic E. coli ‘AcfD precursor’ have been identified with increased solubility as compared to the native AcfD protein that raise a substantially similar immune response in a subject as the native AcfD protein.
    Type: Grant
    Filed: May 29, 2013
    Date of Patent: August 11, 2015
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Laura Serino, Mariagrazia Pizza, Danilo Gomes Moriel, Maria Rita Fontana
  • Publication number: 20150110830
    Abstract: Detoxified variants of the pathogenic E. coli ‘AcfD precursor’ (orf3526) have been identified that raise a substantially similar immune response in a subject as the native AcfD (orB526) protein. The detoxified variants may be further modified to have increased solubility as compared to the native AcfD (orf3526) protein.
    Type: Application
    Filed: October 27, 2014
    Publication date: April 23, 2015
    Inventors: Laura SERINO, Maria Rita FONTANA, Danilo GOMES MORIEL
  • Publication number: 20140356389
    Abstract: Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunising against MNEC infections.
    Type: Application
    Filed: June 2, 2014
    Publication date: December 4, 2014
    Applicants: J. CRAIG VENTER INSTITUTE, INC., NOVARTIS VACCINES AND DIAGNOSTICS SRL
    Inventors: Vega MASIGNANI, Danilo Gomes MORIEL, Francesco BERLANDA SCORZA, Nathalie NORAIS, Maria Rita FONTANA, Mariagrazia PIZZA, Laura SERINO, Herve TETTELIN
  • Patent number: 8871214
    Abstract: Detoxified variants of the pathogenic E. coli ‘AcfD precursor’ (orf3526) have been identified that raise a substantially similar immune response in a subject as the native AcfD (orB526) protein. The detoxified variants may be further modified to have increased solubility as compared to the native AcfD (orf3526) protein.
    Type: Grant
    Filed: July 16, 2010
    Date of Patent: October 28, 2014
    Assignee: Novartis AG
    Inventors: Laura Serino, Danilo Gomes Moriel, Maria Rita Fontana
  • Patent number: 8758764
    Abstract: Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunising against MNEC infections.
    Type: Grant
    Filed: February 17, 2006
    Date of Patent: June 24, 2014
    Assignees: Novartis Vaccines and Diagnostics Srl, J. Craig Venter Institute
    Inventors: Vega Masignani, Danilo Gomes Moriel, Francesco Berlanda Scorza, Nathalie Norais, Maria Rita Fontana, Mariagrazia Pizza, Laura Serino, Herve Tettelin
  • Patent number: 8642050
    Abstract: The invention provides proteins from gonococcus (Neisseria gonorrhoeae), including amino acid sequences, the corresponding nucleotide sequences, expression data, and serological data. The proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. They are also useful for distinguishing between gonococcus and meningococcus and, in particular, between gonococcus and serogroup B meningococcus.
    Type: Grant
    Filed: February 16, 2009
    Date of Patent: February 4, 2014
    Assignee: Novartis AG
    Inventors: Maria Rita Fontana, Mariagrazia Pizza, Vega Masignani, Elisabetta Monaci
  • Publication number: 20130323274
    Abstract: Variants of the pathogenic E. coli ‘AcfD precursor’ have been identified with increased solubility as compared to the native AcfD protein that raise a substantially similar immune response in a subject as the native AcfD protein.
    Type: Application
    Filed: May 29, 2013
    Publication date: December 5, 2013
    Applicant: NOVARTIS AG
    Inventors: Laura SERINO, Mariagrazia PIZZA, Danilo GOMES MORIEL, Maria Rita FONTANA
  • Patent number: 8470341
    Abstract: Variants of the pathogenic E. coli ‘AcfD precursor’ have been identified with increased solubility as compared to the native AcfD protein that raise a substantially similar immune response in a subject as the native AcfD protein.
    Type: Grant
    Filed: February 23, 2009
    Date of Patent: June 25, 2013
    Assignee: Novartis AG
    Inventors: Laura Serino, Mariagrazia Pizza, Danilo Gomes Moriel, Maria Rita Fontana
  • Publication number: 20130004531
    Abstract: Disclosed herein are various polypeptides that can be included in immunogenic compositions specific for pathogenic E. coli strains. The polypeptides have cellular locations which render them accessible to the immune system. The genes encoding the polypeptides were initially identified as being present in uropathogenic strain 536 but absent from non-pathogenic strains.
    Type: Application
    Filed: September 4, 2012
    Publication date: January 3, 2013
    Applicants: Robert Koch Institute, Novartis Vaccines and Diagnostics SRL
    Inventors: Francesco BERLANDA SCORZA, Maria Rita Fontana, Danilo Gomes Moriel, Mariagrazia Pizza, Laura Serino, Jörg Hacker
  • Publication number: 20120207777
    Abstract: Detoxified variants of the pathogenic E. coli ‘AcfD precursor’ (orf3526) have been identified that raise a substantially similar immune response in a subject as the native AcfD (or B526) protein.
    Type: Application
    Filed: July 16, 2010
    Publication date: August 16, 2012
    Applicant: NOVARTIS AG
    Inventors: Laura Serino, Danilo Gomes Moriel, Maria Rita Fontana
  • Publication number: 20120207776
    Abstract: Homologs of the E. coli proteins orf353, bacterial lg-like domain (group 1) protein (orf405), flu antigen 43 (orf1 364), NodT-family outer-membrane-factor-lipoprotein efflux transporter (orf1 767), gspK (orf3515), gspJ (orf3516), toriB-dependent siderophore receptor (orO597), fibrial protein (orf3613), upec-948, upec-1232. A chain precursor of the type-1 fimbria! protein (upec-1875), yapH homolog (upec-2820), hemolysin A (recp-3768), and Sel 1 repeat-containing protein (upec-521 1) from several pathogenic strains of E. coli have been identified with regions within the proteins that are conserved across all E. coli. Fragments corresponding to the conserved regions, especially immunogenic fragments such a linear B-epitopes, are provided.
    Type: Application
    Filed: July 7, 2010
    Publication date: August 16, 2012
    Applicant: NOVARTIS AG
    Inventors: Laura Serino, Danilo Gomes Moriel, Maria Rita Fontana
  • Publication number: 20120058146
    Abstract: Disclosed herein are various genes that can be included in immunogenic compositions specific for pathogenic E. coli strains. The genes are from uropathogenic strains but are absent from non-pathogenic strains, and their encoded proteins have cellular locations which render them accessible to the immune system.
    Type: Application
    Filed: November 9, 2011
    Publication date: March 8, 2012
    Applicant: Novartis Vaccines and Diagnostics SRL
    Inventors: Danilo Gomes Moriel, Francesco Berlanda Scorza, Mariagrazia PIZZA, Laura Serino, Maria Rita Fontana
  • Patent number: 8062644
    Abstract: Disclosed herein are various genes that can be included in immunogenic compositions specific for pathogenic E. coli strains. The genes are from uropathogenic strains but are absent from non-pathogenic strains, and their encoded proteins have cellular locations which render them accessible to the immune system.
    Type: Grant
    Filed: February 17, 2006
    Date of Patent: November 22, 2011
    Assignee: Novartis Vaccines & Diagnostics SRL.
    Inventors: Mariagrazia Pizza, Laura Serino, Francesco Berlanda Scorza, Danilo Gomes Moriel, Maria Rita Fontana
  • Publication number: 20110091492
    Abstract: Variants of the pathogenic E. coli ‘AcfD precursor’ have been identified with increased solubility as compared to the native AcfD protein that raise a substantially similar immune response in a subject as the native AcfD protein.
    Type: Application
    Filed: February 23, 2009
    Publication date: April 21, 2011
    Applicant: NOVARTIS AG
    Inventors: Laura Serino, Mariagrazia Pizza, Danilo Gomes Moriel, Maria Rita Fontana